LCTX — Lineage Cell Therapeutics Share News
0.000.00%
Last trade - 00:00- $252.91m
- $201.01m
- $14.56m
Brief: Lineage Cell Therapeutics Inc Files For Mixed Shelf Of Upto $75 Million - SEC Filing
Brief: Lineage Cell Therapeutics Conducts Sale Of Shares In Oncocyte Corporation
Brief: Lineage Cell Therapeutics Reports Quarterly Loss Per Share Of $0.03
U.S. STOCKS ON THE MOVE-Sonos, Estee Lauder, PPD, ForeScout Tech, Twitter
Lineage Cell Therapeutics: Surges on positive data from eye-disorder treatment study
Brief: Lineage Provides Positive Update On Phase I/Iia Clinical Study Of Opregen®
Brief: Lineage Cell Therapeutics Says Pricing Of Sale Of 2.4 Mln Shares Of Common Stock Of Oncocyte Corp At Price To Buyers Of $2.156 Per Share
Brief: Lineage Provides Update On Patient Enrollment In Phase I/IIa Clinical Study of OpRegen
Lineage Cell Therapeutics: Surges after multiple license deals for intellectual property
Brief: Lineage Cell Therapeutics Enters Into Three Separate License Agreements
Brief: Lineage Cell Therapeutics Says Co & Agex Therapeutics Announce Issuance Of U.S. Patent For Method Of Generating Induced Pluripotent Stem Cells
Brief: AgeX Therapeutics And Lineage Cell Therapeutics Announce Issuance Of U.S. Patent For Method Of Generating Induced Pluripotent Stem Cells
Brief: Lineage Cell Therapeutics Inc - Reported Positive Results From Ongoing Scistar Study Of Opc1
Brief: Lineage Cell Therapeutics Reports Third Quarter Results
Brief: Lineage Cell Therapeutics Presents New Opregen Data
Brief: Lineage Cell Therapeutics Provides Update On Renevia Commercialization Plans
Brief: Lineage Cell Therapeutics Receives CE Mark Approval For Renevia
OncoCyte drops as top investor sells remaining stake in block trade
Brief: Lineage Cell Receives U.S. Patent For Stem-Cell Based Method Of Treating Spinal Cord Injury